AU2021236622A1 - Method and compositions for treating, preventing or limiting the occurrence of viral infection - Google Patents

Method and compositions for treating, preventing or limiting the occurrence of viral infection Download PDF

Info

Publication number
AU2021236622A1
AU2021236622A1 AU2021236622A AU2021236622A AU2021236622A1 AU 2021236622 A1 AU2021236622 A1 AU 2021236622A1 AU 2021236622 A AU2021236622 A AU 2021236622A AU 2021236622 A AU2021236622 A AU 2021236622A AU 2021236622 A1 AU2021236622 A1 AU 2021236622A1
Authority
AU
Australia
Prior art keywords
formula
occurrence
composition
viral infection
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021236622A
Other languages
English (en)
Inventor
Daryl Lee Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Biolife Inc
Original Assignee
Global Biolife Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Biolife Inc filed Critical Global Biolife Inc
Publication of AU2021236622A1 publication Critical patent/AU2021236622A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021236622A 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection Pending AU2021236622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990168P 2020-03-16 2020-03-16
US62/990,168 2020-03-16
PCT/US2021/022538 WO2021188520A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Publications (1)

Publication Number Publication Date
AU2021236622A1 true AU2021236622A1 (en) 2022-10-13

Family

ID=77768366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021236622A Pending AU2021236622A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Country Status (9)

Country Link
US (1) US20230132782A1 (https=)
EP (1) EP4121040A4 (https=)
JP (1) JP2023518390A (https=)
KR (1) KR20230012469A (https=)
CN (1) CN115397410A (https=)
AU (1) AU2021236622A1 (https=)
BR (1) BR112022018504A2 (https=)
CA (1) CA3172162A1 (https=)
WO (1) WO2021188520A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers
CN117462539A (zh) * 2023-12-26 2024-01-30 云南中医药大学 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
CN101701245B (zh) * 2009-10-21 2013-06-19 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
US12257231B2 (en) * 2015-02-13 2025-03-25 Global Biolife Inc. Method and composition for preventing and treating viral infections
US10123991B2 (en) * 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10966954B2 (en) * 2016-05-16 2021-04-06 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10987371B2 (en) * 2017-06-09 2021-04-27 Adaerata, Limited Partnership Methods of preventing or treating filovirus and flavivirus diseases
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
CN113350330B (zh) * 2020-03-06 2023-04-14 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN113244217A (zh) * 2021-06-25 2021-08-13 南开大学 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用

Also Published As

Publication number Publication date
CA3172162A1 (en) 2021-09-23
BR112022018504A2 (pt) 2022-11-29
WO2021188520A1 (en) 2021-09-23
US20230132782A1 (en) 2023-05-04
KR20230012469A (ko) 2023-01-26
CN115397410A (zh) 2022-11-25
JP2023518390A (ja) 2023-05-01
EP4121040A4 (en) 2024-07-17
EP4121040A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
McKee et al. Candidate drugs against SARS-CoV-2 and COVID-19
Mehta et al. Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): a hypothesis
Smee et al. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
CN114340609B (zh) 产生安全量的一氧化氮的药物组合物及其用途
AU2021236622A1 (en) Method and compositions for treating, preventing or limiting the occurrence of viral infection
WO2021195088A1 (en) TGF-Bβ1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2
Bostanghadiri et al. COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
US20130131000A1 (en) Composition Comprising Ligustroflavone, Rhoifolin and Hyperin and Its Pharmaceutical Application
Turner The epidemiology, pathogenesis, and treatment of the common cold
US20050143328A1 (en) Composition and treatment for envelope virus infections
TWI763916B (zh) 藍綠藻萃取物及其製備方法與用途
CN116942823A (zh) Ep300作为靶点在制备治疗急性肝损伤药物中的应用
US20120142731A1 (en) Methods of inhibiting viral infection
Mukherjee et al. Therapeutic options in coronavirus treatment: COVID-19 drug discovery update
Bhattacharjee et al. Covid-19 pandemic: A pragmatic plan for therapeutic intervention
Alenius Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds
JP2011500830A (ja) ウイルス感染を阻害する方法
Diyya et al. Potential therapeutic avenues for COVID-19 therapy
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
CN102526086A (zh) 女贞苷的提取方法及其制备药物用途
RU2642312C1 (ru) Способ профилактики и лечения опасных нейровирусных инфекций
Halim et al. The Role of Conventional and Alternative Therapy in the Treatment of Covid-19: A Review
Sofra To Be or Not to Be Vaccinated
Shawky et al. Anti-SARS-CoV-2 Potential of Marine Fungi-Derived Compounds and Their Roles in COVID-19 Treatment
Chowdhury Approaches in Combating COVID-19